Filter
212
Text search:
API
Featured
Recommendations
12
New Publications
41
Language
Document type
No document type
139
Studies & Reports
26
Guidelines
22
Manuals
11
Strategic & Response Plan
5
Fact sheets
5
Training Material
3
Infographics
1
Countries / Regions
Indonesia
65
India
16
South Africa
7
Global
6
Ethiopia
5
Rwanda
4
Myanmar / Burma
4
Uganda
3
Germany
3
Kenya
3
Tanzania
3
Bangladesh
3
Liberia
2
Ghana
2
South–East Asia Region
2
Sierra Leone
1
Nigeria
1
Senegal
1
Congo, Democratic Republic of
1
Zimbabwe
1
Haiti
1
Nepal
1
Zambia
1
Cambodia
1
Malawi
1
Benin
1
Namibia
1
Peru
1
Eswatini/ Swaziland
1
Brazil
1
Ukraine
1
Botswana
1
Lesotho
1
Sri Lanka
1
East and Southern Africa
1
West and Central Africa
1
Western Pacific Region
1
Western and Central Europe
1
Africa
1
Eastern Europe
1
Authors & Publishers
Publication Years
Category
Countries
135
Clinical Guidelines
16
Pharmacy & Technologies
11
Public Health
10
Capacity Building
3
Women & Child Health
3
Key Resources
2
Toolboxes
Pharmacy
21
COVID-19
12
TB
11
AMR
11
HIV
10
Planetary Health
5
Global Health Education
3
NCDs
3
Natural Hazards
2
Mental Health
2
Disability
1
Conflict
1
Rapid Response
1
Zika
1
Specific Hazards
1
NTDs
1
Namibia guideline for submission of applications for registration of pharmaceuticals for human use in common technical document format.
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M
...
A view of global supply chains, pressure points, and implications for antimicrobial resistance response
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to
...
WHO/HIV/SIP
Accessed: 28.11.2019
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys
...
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys
...
The primary aim of this assessment is to evaluate current approaches to malaria surveillance in Myanmar and to provide a set of practical and feasible recommendations to further strengthen the surveillance system in the short to medium term. The assessment focuses on the surveillance of malaria case
...
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
Web page access : 28.04.2017
Guidance for the prevention of volcanic ash rain: before, during and after the ash rain
Be-Friended to the Volcano : a guidance or manual book for school children in Indonesia of health crisis prevention during the natural disaster
Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotic.
The Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure t
...
PNAS 119 (8) e2113947119 | https://doi.org/10.1073/pnas.2113947119
Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, m
...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s
...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
